136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
Year: 2016
Type: article
Source: Journal of Thoracic Oncology
Authors: M.-J. Ahn, J. Yang, H. Yu, H. Saka, S. Ramalingam, K. Goto, S.-W. Kim, L. Yang, A. Walding, G.R. Oxnard
Institutions: Samsung Medical Center, Sungkyunkwan University, National Taiwan University Hospital, Memorial Sloan Kettering Cancer Center, National Hospital Organization, Nagoya Medical Center, Emory University, Winship Cancer Institute, Asan Medical Center, University of Ulsan, AstraZeneca (United Kingdom), Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2337507927